This treatment is in clinical trials and has not been approved by the FDA or any regulatory authority. It is not available for prescription. Current stage: Phase 3 complete; regulatory filing planned Q1 2026. Estimated approval: 2026–2027 (estimated — not confirmed) — subject to change.
CagriSema
Novo Nordisk · Code: Cagrilintide 2.4 mg + Semaglutide 2.4 mg
A fixed-dose combination of cagrilintide (a long-acting amylin analogue) and semaglutide 2.4 mg in a single weekly injection. Amylin is a hormone co-secreted with insulin that reduces appetite and slows gastric emptying — complementing GLP-1 action through a different pathway.
Quick read · 4 min
- •CagriSema is an investigational drug — it has not yet been approved by any regulatory authority
- •Best trial result so far: up to 22.7% average weight loss
- •Current stage: Phase 3 complete; regulatory filing planned Q1 2026
- •Expected approval: 2026–2027 (estimated — not confirmed) — this is an estimate and not confirmed
Based on clinical trials · No rankings · Every claim linked to source
Last reviewed: March 2026
How it works
Cagrilintide acts on amylin receptors in the brain (particularly the area postrema) to reduce appetite and slow gastric emptying. Combined with semaglutide's GLP-1 receptor action, the two drugs reduce appetite through two distinct but complementary hormonal pathways — producing greater weight loss than semaglutide alone.
Phase 3 trial results
In the following Phase 3 trials, participants were randomly assigned to CagriSema or a dummy pill.
In the REDEFINE 1 trial, 20.4% average weight loss; 22.7% with full adherence. 50.7% reached a healthy BMI. 40.4% achieved ≥25% weight loss. GI side effects reported by 79.6% vs. 39.9% placebo.
In the REDEFINE 2 trial, 13.7% average weight loss; 15.7% with full adherence. Blood sugar (HbA1c) significantly reduced.
Side effects (early-stage data)
Frequencies from Phase 2 trial data. Final Phase 3 safety profile may differ.
Notable findings
- ✓20.4–22.7% weight loss — in the highest range of any drug so far (REDEFINE 1)
- ✓50.7% of participants reached a non-obese BMI in REDEFINE 1
- ✓40.4% achieved ≥25% weight loss in REDEFINE 1
- ✓Significant HbA1c improvement in people with type 2 diabetes (REDEFINE 2)
Context: REDEFINE 1 results fell short of Novo Nordisk's internal target of ≥25% weight loss. The market reacted negatively. However, the 20.4–22.7% result still substantially outperforms semaglutide alone (14.9%) and cagrilintide alone (11.5%) in head-to-head comparisons.
Community insights
These are personal experiences shared in public online communities — not medical advice.
“The GI side effect rate (nearly 80% experiencing some GI events) is notably higher than semaglutide alone — worth discussing with your doctor before choosing this over tirzepatide.”
Sources & references
- [1]REDEFINE 13,417 adults with obesity, no type 2 diabetes · 68 weeks20.4% average weight loss; 22.7% with full adherence. About 1 in 2 participants reached a healthy BMI. GI side effects reported by about 4 in 5 participants on CagriSema vs. 2 in 5 on placebo.New England Journal of Medicine (2025) ↗
- [2]REDEFINE 21,206 adults with obesity and type 2 diabetes · 68 weeks13.7% weight loss (treatment policy); 15.7% with full adherence. Significant HbA1c reduction.New England Journal of Medicine (2025) ↗